Thank you for sharing, bro.
At first, I thought about the ecological implications that could impact birds, bats and frogs that feed on them as this technology is favourable to humans. Then I realized these creatures probably do not exclusively subsist off mosquitoes alone. The potential for mosquito-borne disease eradication (particularly for malaria) could save 250 million lives annually which disproportionately burden African nations. And the hope of freeing up of 1.3% of GDP which is allocated to malaria-control in many SSA countries. In turn public health expenditure could be redirected toward other health priorities.
From what I gather there should be a multi-prong effort in malaria eradication that utilizes existing malaria controls (1) larval-control methods (2) SES improvements (housing, screened windows and A/C) in tandem with novel vector reduction efforts i.e. GM mosquitoes.
Oxitec, UK biotech firm has been testing GM mosquitoes for the last decade.
- Their first-generation of self-limiting male mosquitoes was with Aedse Aegyptus mosquitoes which involved the releasing of 450 K males in a small town in Brazil that reduced their population by 90%.
- The second-generation of their field trials have resulted in a population collapse of 96%.
- Last year (2018/19) they wished to apply their self-limiting mosquito’s technology to malaria spreading mosquitoes.
There are no clear regulatory pathways. And where would one begin testing? Some place with established biosafety frameworks methinks. One could consult the NEPAD Agency African Biosafety Network of Expertise (NEPAD/ABNE) is a biosafety resource network for African regulators and policy makers. In the country with the first pilot for field trials you would need to first consult with local leaders, local government authorities (with interdepartmental collaboration), farmers and communities.
https://www.abim.ch/fileadmin/abim/documents/presentations2014/4_Camilla_Beech_ABIM2014_rev.pdf